SEC Comment Letter for NEKTAR THERAPEUTICS (NKTR) (CIK 0000906709) (NKTR) — Nov 1, 2017
NEKTAR THERAPEUTICS (NKTR) (CIK 0000906709)
Date: Nov. 1, 2017 · CIK: 0000906709 · Accession: 0000000000-17-038655
AI Filing Summary & Sentiment
File numbers found in text: 000-24006
Letter
November 1, 2017 Gil M. Labrucherie Senior Vice President and Chief Financial Officer Nektar Therapeutics 455 Mission Bay Boulevard South San Francisco, California 94158 Re:Nektar Therapeutics Form 10-K for the Fiscal Year Ended December 31, 2016 Filed March 1, 2017 File No. 000-24006 Dear Mr. Labrucherie: We have limited our review of your filing to the financial statements and related disclosures and have the following comment. In our comment we may ask you to provide us with information so we may better understand your disclosure. Please respond to the comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to the comment, we may have additional comments. Form 10-K for the Fiscal Year Ended December 31, 2016 Management’s Discussion and Analysis of Financial Condition and Results of Operations Results of Operations Cost of goods sold , page 50 1.You disclose that you have a manufacturing arrangement with a partner that includes a fixed price which is less than the fully burdened manufacturing cost for the reagent and that you expect this situation with this partner to continue in future years. Please tell us how you determined whether an adjustment to the cost basis of your inventory was warranted pursuant to ASC 330-10-35-1. Please also quantify for us the sales, cost of good sold and gross profit for this product for your most recent annual and interim periods.
FirstName LastNameGil M. Labrucherie Comapany NameNektar Therapeutics June 16, 2017 Page 2 FirstName LastName Gil M. Labrucherie Nektar Therapeutics November 1, 2017 Page 2 In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. You may contact Ibolya Ignat, Senior Staff Accountant, at (202) 551-3636 or Angela Connell, Accounting Branch Chief, at (202) 551-3426 with any questions. Division of Corporation Finance Office of Healthcare & Insurance
Show Raw Text
November 1, 2017
Gil M. Labrucherie
Senior Vice President and Chief Financial Officer
Nektar Therapeutics
455 Mission Bay Boulevard South
San Francisco, California 94158
Re:Nektar Therapeutics
Form 10-K for the Fiscal Year Ended December 31, 2016
Filed March 1, 2017
File No. 000-24006
Dear Mr. Labrucherie:
We have limited our review of your filing to the financial statements and related
disclosures and have the following comment. In our comment we may ask you to provide us
with information so we may better understand your disclosure.
Please respond to the comment within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe our
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to the comment, we may have additional comments.
Form 10-K for the Fiscal Year Ended December 31, 2016
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Results of Operations
Cost of goods sold , page 50
1.You disclose that you have a manufacturing arrangement with a partner that includes a
fixed price which is less than the fully burdened manufacturing cost for the reagent and
that you expect this situation with this partner to continue in future years. Please tell us
how you determined whether an adjustment to the cost basis of your inventory was
warranted pursuant to ASC 330-10-35-1. Please also quantify for us the sales, cost of
good sold and gross profit for this product for your most recent annual and interim
periods.
FirstName LastNameGil M. Labrucherie
Comapany NameNektar Therapeutics
June 16, 2017 Page 2
FirstName LastName
Gil M. Labrucherie
Nektar Therapeutics
November 1, 2017
Page 2
In closing, we remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
You may contact Ibolya Ignat, Senior Staff Accountant, at (202) 551-3636 or Angela
Connell, Accounting Branch Chief, at (202) 551-3426 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance